Proudly Agripreneurs! Learning from 24 young African business leaders

This booklet highlights key elements of the publication Ils l’ont fait ! published by CTA in collaboration with MediaProd from Burkina Faso, which outlines the achievements of 24 entrepreneurs that have been featured by Agribusiness TV. CTA wants to reveal the impacts these agripreneurs have had, and encourage other young people to take inspiration, so they too can better invest their efforts in agriculture. The booklet introduces the 24 young entrepreneurs and explains how they are addressing the key youth agripreneurship challenges they are facing

Ils l'ont fait : Être jeune et entreprendre dans le secteur agricole

Avec plus d’un milliard d’habitants, l’Afrique est l’une des régions les plus jeunes et dynamiques au monde. Le continent africain compte 60 % de jeunes de moins de 35 ans et 420 millions ont entre 15 à 35 ans, un chiffre qui devrait doubler d’ici à 2040. L’objectif de cette publication est de valoriser les réalisations de 24 entrepreneurs promus par Agribusiness TV afin de présenter un éventail aussi riche que représentatif de la diversité des initiatives. Nous souhaitons également en montrer les impacts et encourager d’autres jeunes à s’inspirer des modèles proposés pour mieux s’investir dans l’agriculture. Au-delà de la présentation des entrepreneurs, de leur parcours atypique, chaque histoire traite à sa manière de questions aussi diverses et cruciales que l'accès au financement, l'impact des actions menées, les relations entamées avec d'autres jeunes et l'utilisation des technologies numériques dans l'agripreneuriat

Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial

Abstract Lynch syndrome (LS) is the most common cause of inherited colorectal cancer (CRC) and confers a high lifetime risk of CRC estimated to be up to 60%. Colonoscopy is recommended every 2 years in LS patients above the 20–25-year-old age bracket, and every year when colonic neoplasia has been detected. Efficient chemoprevention has the potential to represent a cost-effective intervention in these high-risk patients and could allow a delay in colonoscopy surveillance. Several epidemiological studies have shown that regular use of low dose aspirin is associated with a 20 to 30% reduction in the risk of sporadic colonic adenomas and colorectal cancer regardless of family risk. However, in recent large randomized trials in specific populations, aspirin use showed no protection for colorectal cancer. A prospective randomized CAPP-2 trial evaluated the effect of aspirin use in LS patients. The primary analysis of this trial showed no significant decrease in CRC in LS patients under daily aspirin. However, a preplanned secondary analysis after an extended follow-up showed a significant reduced risk of CRC in the aspirin group in the per-protocol analysis. The real effect and clinical benefit of aspirin are still to be consolidated in this population. The AAS-Lynch trial—a prospective, multicentric, double-blind, placebo-controlled, randomized clinical trial—was designed to investigate if daily aspirin therapy, at a dose of 100 or 300 mg, would decrease the occurrence or recurrence of colorectal adenomas in patients under 75 years of age, compared with placebo. Trial registration ClinicalTrials.gov NCT02813824 . Registered on 27 June 2016. The trial was prospectively registered